|[December 03, 2012]
Avedro Appoints Satish Herekar as Science Fellow
WALTHAM, Mass. --(Business Wire)--
Avedro, Inc. announced today that it has named Satish Herekar as its new
Science Fellow. Herekar is a world-renowned researcher and entrepreneur
in the fields of trans-epithelial drug delivery and accelerated
cross-linking, and is co-Founder of Seros Medical. In his new role, he
will be responsible for continuing Avedro's momentum in cutting-edge
trans-epithelial cross-linking research and innovation.
Prior to joining Avedro, Herekar was co-Founder of Seros Medical/
PriaVision, where he initiated research and development in
trans-epithelial riboflavin delivery techniques for rapid cross-linking,
improved UVA crosslinking delivery devices, and other advanced uses of
cross-linking for refractive correction. Herekar previously held roles
of increasing seniority at Sunrise Technologies, Sepragen, Acuson,
Cooper Vision, and GeneralElectric. He is also the Founder of Bridge
"Satish is a talented addition to the Avedro Science team," said David
Muller, PhD, CEO of Avedro. "As leaders and innovators in the field of
accelerated cross-linking, we are pleased to have one of the world's
most prolific researchers join our team to help continue the profound
research momentum we have already achieved, and bring it to the next
"I am honored to join the outstanding research team at Avedro,"
commented Herekar. "I look forward to taking a significant role in a
team of scientists which is at the cutting edge of research in this
Herekar will be working with Avedro's proprietary family of riboflavin
formulations and the KXL® System for Accelerated Cross-linking. In this
role, he will be reporting directly to the Chief Scientific Officer.
About Avedro, Inc.
Avedro is a privately held medical device and pharmaceutical company
advancing the science and technology of corneal cross-linking. The
Company's advanced cross-linking technology makes the treatment of
keratoconus and post-LASIK ectasia faster, while also making possible an
entirely new cross-linking procedure, Lasik Xtra®, intra-operative
cross-linking following the creation of the LASIK flap and/or excimer
laser ablation during LASIK or PRK. More than 50,000 eyes around the
world have been treated with Avedro's KXL ® System for Accelerated
Cross-linking. Outside the US, Avedro has obtained CE Mark for its KXL
System and its family of riboflavin products. Avedro's products are not
for sale in the US.
[ Back To Technology News's Homepage ]